Hero

Celyad Announces First Quarter 2017 Business Update

1

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

2

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

3

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad initiates second dose escalation in THINK trial in first US patient

4

Celyad initiates second dose escalation in THINK trial in first US patient

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

5

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Bringing breakthrough pioneering therapies to patients with life-threatening diseases

6

Bringing breakthrough pioneering therapies to patients with life-threatening diseases

Celyad issues a White Paper about CAR T NKR-2

7

Celyad issues a White Paper about CAR T NKR-2

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Discover all news

Carousel

Social Feed

Celyad Announces First Quarter 2017 Business Update https://t.co/Lh5CJbawWs

4 days ago

Celyad Announces First Quarter 2017 Business Update https://t.co/Lh5CJbawWs

David Gilham,our R&D VP,is a key contributor to BioVox’s white paper on cancer immunotherapy showcasing innovators… https://t.co/W5E9aie7aq

5 days ago

David Gilham,our R&D VP,is a key contributor to BioVox’s white paper on cancer immunotherapy showcasing innovators… https://t.co/W5E9aie7aq

5 great open positions @CelyadSA Ready to take up the challenge? #Jobs #Clinical #QC #QA #administrative… https://t.co/QMqcsTc1Ly

6 days ago

5 great open positions @CelyadSA Ready to take up the challenge? #Jobs #Clinical #QC #QA #administrative… https://t.co/QMqcsTc1Ly

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure® https://t.co/zIP2reFMry

1 week ago

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure® https://t.co/zIP2reFMry

Celyad Announces First Quarter 2017 Business Update https://t.co/Lh5CJbawWs

4 days ago

Celyad Announces First Quarter 2017 Business Update https://t.co/Lh5CJbawWs

David Gilham,our R&D VP,is a key contributor to BioVox’s white paper on cancer immunotherapy showcasing innovators… https://t.co/W5E9aie7aq

5 days ago

David Gilham,our R&D VP,is a key contributor to BioVox’s white paper on cancer immunotherapy showcasing innovators… https://t.co/W5E9aie7aq

5 great open positions @CelyadSA Ready to take up the challenge? #Jobs #Clinical #QC #QA #administrative… https://t.co/QMqcsTc1Ly

6 days ago

5 great open positions @CelyadSA Ready to take up the challenge? #Jobs #Clinical #QC #QA #administrative… https://t.co/QMqcsTc1Ly

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure® https://t.co/zIP2reFMry

1 week ago

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure® https://t.co/zIP2reFMry